1. Home
  2. THW vs DCTH Comparison

THW vs DCTH Comparison

Compare THW & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn World Healthcare Fund Shares of Beneficial Interest

THW

abrdn World Healthcare Fund Shares of Beneficial Interest

N/A

Current Price

$12.99

Market Cap

484.8M

Sector

Finance

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$14.95

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
THW
DCTH
Founded
N/A
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
484.8M
578.4M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
THW
DCTH
Price
$12.99
$14.95
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $24.00
AVG Volume (30 Days)
104.1K
★ 279.8K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
$24.61
Revenue Next Year
N/A
$24.27
P/E Ratio
★ N/A
$370.50
Revenue Growth
N/A
N/A
52 Week Low
$11.18
$8.12
52 Week High
$14.50
$17.42

Technical Indicators

Market Signals
Indicator
THW
DCTH
Relative Strength Index (RSI) 55.46 47.82
Support Level $12.76 $14.52
Resistance Level $13.76 $16.51
Average True Range (ATR) 0.28 0.54
MACD 0.10 0.05
Stochastic Oscillator 72.65 58.21

Price Performance

Historical Comparison
THW
DCTH

About THW abrdn World Healthcare Fund Shares of Beneficial Interest

Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: